声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议2025年9月7日,第一三共和默沙东共同宣布IDeate-Lung01 II期试验结果显示,ifinatamab deruxtecan(I-DXd)在既往接受过治疗的广泛期小细胞肺癌(ES-SCLC)患者中展现出具有临床意义的缓解率。第一三共现已将研究结果...
Source Link声明:因水平有限,错误不可避免,或有些信息非最及时,欢迎留言指出。本文仅作医疗健康相关药物介绍,非治疗方案推荐(若涉及);本文不构成任何投资建议2025年9月7日,第一三共和默沙东共同宣布IDeate-Lung01 II期试验结果显示,ifinatamab deruxtecan(I-DXd)在既往接受过治疗的广泛期小细胞肺癌(ES-SCLC)患者中展现出具有临床意义的缓解率。第一三共现已将研究结果...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.